MX2017007390A - Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales. - Google Patents

Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales.

Info

Publication number
MX2017007390A
MX2017007390A MX2017007390A MX2017007390A MX2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A
Authority
MX
Mexico
Prior art keywords
neoplasms
central nervous
immune checkpoint
checkpoint inhibitors
nervous systems
Prior art date
Application number
MX2017007390A
Other languages
English (en)
Spanish (es)
Inventor
Coric Vladimir
CHENG Shinta
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2017007390A publication Critical patent/MX2017007390A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2017007390A 2014-12-16 2015-12-16 Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales. MX2017007390A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092783P 2014-12-16 2014-12-16
US201562261130P 2015-11-30 2015-11-30
PCT/US2015/066177 WO2016100561A2 (en) 2014-12-16 2015-12-16 Use of immune checkpoint inhibitors in central nervous systems neoplasms

Publications (1)

Publication Number Publication Date
MX2017007390A true MX2017007390A (es) 2017-11-06

Family

ID=56127849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007390A MX2017007390A (es) 2014-12-16 2015-12-16 Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales.

Country Status (9)

Country Link
US (3) US20180133313A1 (https=)
EP (1) EP3233123A4 (https=)
JP (2) JP2018500332A (https=)
CN (1) CN106999590A (https=)
BR (1) BR112017010101A2 (https=)
CA (1) CA2969338A1 (https=)
MX (1) MX2017007390A (https=)
RU (1) RU2726996C1 (https=)
WO (1) WO2016100561A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
EP3288982A1 (en) 2015-04-28 2018-03-07 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
US20160362489A1 (en) * 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
KR102055396B1 (ko) 2015-08-11 2019-12-12 우시 바이올로직스 (케이만) 인코포레이티드 신규한 항-pd-1 항체
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
WO2018029124A1 (en) * 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
GB201618291D0 (en) * 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
IL303038B2 (en) 2016-12-05 2024-08-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
DE102017119868B4 (de) * 2017-07-12 2021-05-27 Bruker Daltonik Gmbh Feuchtestabilisierung bei der Präparation von Proben für die Spektrometrie
JP7159007B2 (ja) * 2017-11-01 2022-10-24 小野薬品工業株式会社 脳腫瘍の治療のための医薬
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
TW202015732A (zh) 2018-05-31 2020-05-01 日商小野藥品工業股份有限公司 免疫檢查點阻礙藥的有效性判定用生物標記
EP3941467A4 (en) * 2019-03-19 2022-12-21 ChemoCentryx, Inc. MULTIPLE THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR
KR102873347B1 (ko) * 2019-09-10 2025-10-17 노보큐어 게엠베하 암 세포에 교번 전기장을 적용하고 체크포인트 억제제를 투여하여 암 세포의 활력성을 감소시키는 방법
JP7772700B2 (ja) * 2019-12-19 2025-11-18 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 神経膠芽腫を処置するための方法
EP4082577A4 (en) * 2019-12-27 2024-01-03 Zeria Pharmaceutical Co., Ltd. CANCER TREATMENT METHOD AND DRUG
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
EP4149512A4 (en) * 2020-05-12 2024-06-05 Board of Regents, The University of Texas System Methods for treating glioblastoma
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022032312A1 (en) * 2020-08-07 2022-02-10 Northwestern University Methods of treating malignant glioblastoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102203132A (zh) * 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
KR101814408B1 (ko) * 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
RU2402360C1 (ru) * 2009-07-08 2010-10-27 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения злокачественной глиомы головного мозга
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
WO2012177624A2 (en) * 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10392442B2 (en) * 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

Also Published As

Publication number Publication date
JP2018500332A (ja) 2018-01-11
CN106999590A (zh) 2017-08-01
WO2016100561A2 (en) 2016-06-23
US20240238416A1 (en) 2024-07-18
BR112017010101A2 (pt) 2018-01-02
EP3233123A2 (en) 2017-10-25
US20180133313A1 (en) 2018-05-17
WO2016100561A3 (en) 2016-08-18
CA2969338A1 (en) 2016-06-23
EP3233123A4 (en) 2018-05-09
US20210000953A1 (en) 2021-01-07
RU2726996C1 (ru) 2020-07-17
JP2021181482A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2017007390A (es) Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales.
MX2022002364A (es) Anticuerpos anti-pd-l1.
NZ728688A (en) Anti-pd-1 antibodies
MX2020001272A (es) Anticuerpos dirigidos contra interleucina-33 (il-33).
SMT202600008T1 (it) Metodo per trattare il cancro usando un inibitore di checkpoint immunitario; anticorpo che si lega a recettore di morte programmata-1 (pd-1) o ligando di morte programmata 1 (pd-l1)
MY195110A (en) Antibodies to PD-1 and uses Thereof
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12020500075A1 (en) Checkpoint inhibitor bispecific antibodies
EP3572430A3 (en) Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
EA201790926A1 (ru) Комбинированное лечение злокачественного новообразования
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
MX2017000857A (es) Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata.
EA201691376A1 (ru) Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака
NZ728674A (en) Signalling system
MX2015012428A (es) Tratamiento contra enfermedades mediadas th2 por inhibicion de bromodominios.
CO2017012988A2 (es) Agentes, usos y métodos para el tratamiento
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
IL250137A0 (en) Method for inhibiting intracellular activated ras using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof
MX2019005089A (es) Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso.
MX2017007097A (es) Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
MX2019002349A (es) Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control.